Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024303920> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2024303920 endingPage "288" @default.
- W2024303920 startingPage "284" @default.
- W2024303920 abstract "Randomized trials demonstrated the superiority of chemoimmunotherapy over chemotherapy in the frontline treatment of CLL. Based on favorable experience with the addition of mitoxantrone (M) to fludarabine (F) plus cyclophosphamide (C), we designed a pilot study testing the combination of FCM plus rituximab (R). Thirty patients with previously untreated, symptomatic CLL, <70 years, and beta-2-microglobulin <twice upper limit of normal were evaluated. Treatment consisted of F 25 mg/m2/day on days 2–4, C 250 mg/m2/day on days 2–4, M 6 mg/m2 on day 2, and R 375 mg/m2 on day 1. For cycles 2–6, FCM started day 1 together with R 500 mg/m2. Pegfilgrastim was administered with each cycle. Cycles were repeated every 4–6 weeks. Complete remission (CR) was achieved in 83% of 30 patients, nodular partial response in 10%, and partial response in 3%. The overall response rate was 96%. Sixteen of 24 CR patients (67%) achieved a flow cytometry response with <1% marrow CD5/CD19-positive cells and 13 of 21 CR patients (62%) were MRD-negative by molecular evaluation for clonal IgVH. With a median follow up of 38.5 months, the median time to treatment failure (TTF) has not been reached. A comparison with a historical group of FCR-treated patients showed no significant differences with respect to response and toxicities. FCM-R is highly active in patients < 70 years with favorable beta-2-microglobulin levels and previously untreated CLL. Outcome does not differ from FCR-treated patients." @default.
- W2024303920 created "2016-06-24" @default.
- W2024303920 creator A5006104041 @default.
- W2024303920 creator A5027575595 @default.
- W2024303920 creator A5028845635 @default.
- W2024303920 creator A5035354255 @default.
- W2024303920 creator A5046097970 @default.
- W2024303920 creator A5089428686 @default.
- W2024303920 date "2010-03-01" @default.
- W2024303920 modified "2023-10-12" @default.
- W2024303920 title "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years" @default.
- W2024303920 cites W1841628176 @default.
- W2024303920 cites W2107334098 @default.
- W2024303920 cites W2117648265 @default.
- W2024303920 cites W2119900897 @default.
- W2024303920 cites W2125134816 @default.
- W2024303920 cites W2129285584 @default.
- W2024303920 cites W2163790170 @default.
- W2024303920 cites W2348637346 @default.
- W2024303920 cites W2508352779 @default.
- W2024303920 cites W2556217933 @default.
- W2024303920 cites W2556997696 @default.
- W2024303920 cites W319074543 @default.
- W2024303920 cites W60865865 @default.
- W2024303920 doi "https://doi.org/10.1016/j.leukres.2009.07.008" @default.
- W2024303920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4845644" @default.
- W2024303920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19646755" @default.
- W2024303920 hasPublicationYear "2010" @default.
- W2024303920 type Work @default.
- W2024303920 sameAs 2024303920 @default.
- W2024303920 citedByCount "43" @default.
- W2024303920 countsByYear W20243039202012 @default.
- W2024303920 countsByYear W20243039202013 @default.
- W2024303920 countsByYear W20243039202014 @default.
- W2024303920 countsByYear W20243039202015 @default.
- W2024303920 countsByYear W20243039202016 @default.
- W2024303920 countsByYear W20243039202017 @default.
- W2024303920 countsByYear W20243039202019 @default.
- W2024303920 crossrefType "journal-article" @default.
- W2024303920 hasAuthorship W2024303920A5006104041 @default.
- W2024303920 hasAuthorship W2024303920A5027575595 @default.
- W2024303920 hasAuthorship W2024303920A5028845635 @default.
- W2024303920 hasAuthorship W2024303920A5035354255 @default.
- W2024303920 hasAuthorship W2024303920A5046097970 @default.
- W2024303920 hasAuthorship W2024303920A5089428686 @default.
- W2024303920 hasBestOaLocation W20243039202 @default.
- W2024303920 hasConcept C126322002 @default.
- W2024303920 hasConcept C141071460 @default.
- W2024303920 hasConcept C21957315 @default.
- W2024303920 hasConcept C2776694085 @default.
- W2024303920 hasConcept C2776755627 @default.
- W2024303920 hasConcept C2779263901 @default.
- W2024303920 hasConcept C2779338263 @default.
- W2024303920 hasConcept C2780653079 @default.
- W2024303920 hasConcept C2780790343 @default.
- W2024303920 hasConcept C2780923524 @default.
- W2024303920 hasConcept C71924100 @default.
- W2024303920 hasConcept C90924648 @default.
- W2024303920 hasConceptScore W2024303920C126322002 @default.
- W2024303920 hasConceptScore W2024303920C141071460 @default.
- W2024303920 hasConceptScore W2024303920C21957315 @default.
- W2024303920 hasConceptScore W2024303920C2776694085 @default.
- W2024303920 hasConceptScore W2024303920C2776755627 @default.
- W2024303920 hasConceptScore W2024303920C2779263901 @default.
- W2024303920 hasConceptScore W2024303920C2779338263 @default.
- W2024303920 hasConceptScore W2024303920C2780653079 @default.
- W2024303920 hasConceptScore W2024303920C2780790343 @default.
- W2024303920 hasConceptScore W2024303920C2780923524 @default.
- W2024303920 hasConceptScore W2024303920C71924100 @default.
- W2024303920 hasConceptScore W2024303920C90924648 @default.
- W2024303920 hasIssue "3" @default.
- W2024303920 hasLocation W20243039201 @default.
- W2024303920 hasLocation W20243039202 @default.
- W2024303920 hasLocation W20243039203 @default.
- W2024303920 hasLocation W20243039204 @default.
- W2024303920 hasOpenAccess W2024303920 @default.
- W2024303920 hasPrimaryLocation W20243039201 @default.
- W2024303920 hasRelatedWork W1993231339 @default.
- W2024303920 hasRelatedWork W2024303920 @default.
- W2024303920 hasRelatedWork W2033848481 @default.
- W2024303920 hasRelatedWork W2077195134 @default.
- W2024303920 hasRelatedWork W2080166597 @default.
- W2024303920 hasRelatedWork W2097852595 @default.
- W2024303920 hasRelatedWork W2400758223 @default.
- W2024303920 hasRelatedWork W2557262035 @default.
- W2024303920 hasRelatedWork W267697690 @default.
- W2024303920 hasRelatedWork W2576487797 @default.
- W2024303920 hasVolume "34" @default.
- W2024303920 isParatext "false" @default.
- W2024303920 isRetracted "false" @default.
- W2024303920 magId "2024303920" @default.
- W2024303920 workType "article" @default.